FENNEC PHARMACEUTICALS INC.

For the period ended Dec 31, 2024. Filed Mar 26, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 26, 2025

FENC$10.83+10.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations


· · Year Ended
· · December 31, · · December 31,
	2024		2023

Revenue
Product sales, net		$29,580		$21,252
Licensing revenue		17,958		—
Total net revenues		47,538		21,252

Operating expenses:
Cost of product sales		3,184		1,259
Research and development		307		56
Selling and marketing		18,426		12,123
General and administrative		23,053		20,585

Total operating expenses		44,970		34,023
Income / (Loss) from operations		2,568		(12,771)

Other (expense)/income
Unrealized foreign exchange (loss)/gain		(82)		5
Amortization expense		(89)		(287)
Unrealized loss on securities		(81)		(39)
Interest income		1,682		441
Interest expense		(4,069)		(3,394)
Total other expense		(2,639)		(3,274)
Loss before income tax		(71)		(16,045)
Income tax		(365)		—
Net loss		$(436)		$(16,045)

Basic net loss per common share		$(0.02)		$(0.60)
Diluted net loss per common share		$(0.02)		$(0.60)
Weighted-average number of common shares outstanding basic		27,294		26,574
Weighted-average number of common shares outstanding diluted		27,294		26,574

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.